170 related articles for article (PubMed ID: 19504093)
1. Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging.
Tran TA; Rosik D; Abrahmsén L; Sandström M; Sjöberg A; Wållberg H; Ahlgren S; Orlova A; Tolmachev V
Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1864-73. PubMed ID: 19504093
[TBL] [Abstract][Full Text] [Related]
2. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus.
Lindberg H; Hofström C; Altai M; Honorvar H; Wållberg H; Orlova A; Ståhl S; Gräslund T; Tolmachev V
Tumour Biol; 2012 Jun; 33(3):641-51. PubMed ID: 22249974
[TBL] [Abstract][Full Text] [Related]
4. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
[TBL] [Abstract][Full Text] [Related]
5. Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.
Engfeldt T; Orlova A; Tran T; Bruskin A; Widström C; Karlström AE; Tolmachev V
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):722-733. PubMed ID: 17146656
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of 99mTc-peptide-ZHER2:342 Affibody® molecule for in vivo molecular imaging.
Zhang JM; Zhao XM; Wang SJ; Ren XC; Wang N; Han JY; Jia LZ
Br J Radiol; 2014 Jan; 87(1033):20130484. PubMed ID: 24273251
[TBL] [Abstract][Full Text] [Related]
7. Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake.
Ekblad T; Tran T; Orlova A; Widström C; Feldwisch J; Abrahmsén L; Wennborg A; Karlström AE; Tolmachev V
Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2245-55. PubMed ID: 18594815
[TBL] [Abstract][Full Text] [Related]
8. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
[TBL] [Abstract][Full Text] [Related]
9. Direct comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging.
Rosik D; Orlova A; Malmberg J; Altai M; Varasteh Z; Sandström M; Karlström AE; Tolmachev V
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):693-702. PubMed ID: 22170322
[TBL] [Abstract][Full Text] [Related]
10. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount.
Tolmachev V; Rosik D; Wållberg H; Sjöberg A; Sandström M; Hansson M; Wennborg A; Orlova A
Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):613-22. PubMed ID: 19838701
[TBL] [Abstract][Full Text] [Related]
11. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
Tran T; Engfeldt T; Orlova A; Sandström M; Feldwisch J; Abrahmsén L; Wennborg A; Tolmachev V; Karlström AE
Bioconjug Chem; 2007; 18(6):1956-64. PubMed ID: 17944527
[TBL] [Abstract][Full Text] [Related]
12. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.
Malmberg J; Perols A; Varasteh Z; Altai M; Braun A; Sandström M; Garske U; Tolmachev V; Orlova A; Karlström AE
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):481-92. PubMed ID: 22322933
[TBL] [Abstract][Full Text] [Related]
14. A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue.
Tolmachev V; Velikyan I; Sandström M; Orlova A
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1356-67. PubMed ID: 20130858
[TBL] [Abstract][Full Text] [Related]
15. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule.
Engfeldt T; Tran T; Orlova A; Widström C; Feldwisch J; Abrahmsen L; Wennborg A; Karlström AE; Tolmachev V
Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1843-53. PubMed ID: 17565496
[TBL] [Abstract][Full Text] [Related]
16. The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.
Tolmachev V; Wållberg H; Andersson K; Wennborg A; Lundqvist H; Orlova A
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1460-8. PubMed ID: 19430786
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging.
Honarvar H; Jokilaakso N; Andersson K; Malmberg J; Rosik D; Orlova A; Karlström AE; Tolmachev V; Järver P
Nucl Med Biol; 2013 Apr; 40(3):378-86. PubMed ID: 23357083
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.
Tolmachev V; Xu H; Wållberg H; Ahlgren S; Hjertman M; Sjöberg A; Sandström M; Abrahmsén L; Brechbiel MW; Orlova A
Bioconjug Chem; 2008 Aug; 19(8):1579-87. PubMed ID: 18620447
[TBL] [Abstract][Full Text] [Related]
19. Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate.
Tolmachev V; Feldwisch J; Lindborg M; Baastrup B; Sandström M; Orlova A
Nucl Med Biol; 2011 Jul; 38(5):697-706. PubMed ID: 21718945
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation of
Oroujeni M; Rinne SS; Vorobyeva A; Loftenius A; Feldwisch J; Jonasson P; Chernov V; Orlova A; Frejd FY; Tolmachev V
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
